FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Desire Stack

Sexual Healthbeginner

83

シナジー

83
Share
ペプチド

2

平均日用量mcg

1,774

レベル

beginner

追加

May 17, 2026

概要

The Desire Stack pairs the only FDA-approved peptide for sexual desire disorders with the "bonding hormone" to address both physiological arousal and emotional intimacy. PT-141 (Bremelanotide, brand name Vyleesi) is a cyclic heptapeptide melanocortin-4 receptor (MC4R) agonist that acts directly in the central nervous system to stimulate sexual desire. Unlike PDE5 inhibitors (Viagra, Cialis) that only address erectile mechanics, PT-141 operates upstream — in the brain''s desire and arousal pathways. It was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, and is used off-label by men for desire-based erectile dysfunction. Clinical trials demonstrated significant increases in desire, arousal, and sexual satisfaction scores. Oxytocin is a nine-amino-acid neuropeptide naturally released during physical touch, orgasm, and pair-bonding activities. When administered nasally, it crosses the blood-brain barrier and enhances feelings of trust, emotional connection, and physical pleasure sensitivity. Research demonstrates that intranasal oxytocin increases partner attractiveness perception, promotes eye contact, and enhances the rewarding aspects of social and sexual interaction. It modulates the reward system (ventral tegmental area and nucleus accumbens) to strengthen the association between partner and pleasure. The combination addresses sexual health holistically: PT-141 activates the neurological desire circuitry (hypothalamic melanocortin system), while oxytocin enhances the emotional and relational context that makes desire meaningful. PT-141 is typically administered 45 minutes before anticipated activity, with effects lasting 12-24 hours. Oxytocin nasal spray is used 20-30 minutes beforehand. The beginner classification reflects the as-needed dosing (no daily commitment), though users should be aware of PT-141''s common side effects including transient nausea (in approximately 40% of first-time users), facial flushing, and potential blood pressure changes.

投与プロトコル

PT-141 (Bremelanotide)

as-needed· subcutaneous

PT-141 (Bremelanotide)について詳しく読む →

1,750 mcg

1回の投与あたり

24 mcg

1回の投与あたり

目標と証拠

Sexual desireArousalIntimacyBondingSexual function
証拠ランク:人間臨床試験(RCT)

警告

  • PT-141 can cause temporary nausea, flushing, and blood pressure changes. Do not use with PDE5 inhibitors. Oxytocin nasal sprays are not FDA-approved but widely compounded.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。